Skip to main
SBRA
SBRA logo

SBRA Stock Forecast & Price Target

SBRA Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 0%
Buy 38%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Sabra Health Care REIT is experiencing significant improvements in occupancy and rent coverage, which contribute positively to the company's overall financial stability and growth potential. The expected recovery in the seniors housing managed portfolio is anticipated to enhance the company's leverage profile, positioning Sabra to pursue growth opportunities effectively. Additionally, the increase in the forecasted Funds from Operations (FFO) estimate for 2025 to $1.54 per share, driven by strategic financial maneuvers, showcases underlying strength and an attractive investment thesis in the healthcare real estate sector.

Bears say

Sabra Health Care REIT faces significant challenges due to the unpredictable performance of individual operators, many of whom struggle to meet rent obligations in the current inflationary environment. Moreover, the company is positioned near the high end of its 10-year stock valuation range, indicating limited potential for immediate earnings growth from acquisitions, particularly given the competitive landscape of the healthcare REIT sector. Additionally, Sabra's leverage levels are not as favorable compared to several of its peers, further contributing to a negative outlook on its financial stability.

SBRA has been analyzed by 8 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 38% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sabra Health Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sabra Health Care (SBRA) Forecast

Analysts have given SBRA a Hold based on their latest research and market trends.

According to 8 analysts, SBRA has a Hold consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sabra Health Care (SBRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.